Stay informed and up to date with the latest news and updates of Cyprumed.
Cyprumed announces the appointment of Martin E. Judge as Chief Business Officer, effective immediately.
With deep experience in pharma/biotech licensing, strategy and establishment of partnerships, Martin will play a key role in advancing our mission and executing our strategy. He has a background in life sciences and technologies in areas relevant to the Pharma industry based on his education (PhD in Basic Medical Sciences, New York University) and professional experience in R&D and Business Development at Novo Nordisk.
Welcome to the team!
Cyprumed signs feasibility agreements with two additional top 20 pharma companies
Cyprumed publishes original research article on oral peptide delivery in Journal of Controlled Release.
Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics
Grant of FFG Funding (Österreichische Forschungsförderung)
Cyprumed attends 2nd Biotech Austria Summit
Japan patent granted
Cyprumed enters into additional pharma collaborations
Cyprumed expands its lab capabilities to strengthen bioanalytics
Austrian Research Promotion Agency (FFG) reports on success stories of funded projects (incl. Cyprumed, Biontech and others)
Are you interested in a possible collaboration? Do you have any questions? We look forward to hearing from you!